MARKET

HSTO

HSTO

Conatus Pharmaceuticals
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.305
+0.105
+8.75%
Opening 13:25 02/24 EST
OPEN
1.250
PREV CLOSE
1.200
HIGH
1.380
LOW
1.230
VOLUME
2.17M
TURNOVER
--
52 WEEK HIGH
7.50
52 WEEK LOW
0.7490
MARKET CAP
37.89M
P/E (TTM)
-0.4471
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
BRIEF-Histogen Announces Week 26 HST-001 Study Results For The Treatment Of Androgenic Alopecia In Men
reuters.com · 02/16 13:54
Histogen Says HST-001 Found To Be 'Safe And Well Tolerated' With No Serious Adverse Events; Says Planning Underway For Next Clinical Study In U.S.
Histogen Announces Week 26 HST-001 Study Results for the Treatment of Androgenic Alopecia in Men HST-001 Found to be Safe and Well Tolerated with No Serious Adverse Events Planning Underway for Next Clinical Study in
Benzinga · 02/16 13:13
Histogen Announces Week 26 HST-001 Study Results for the Treatment of Androgenic Alopecia in Men
HST-001 Found to be Safe and Well Tolerated with No Serious Adverse Events Planning Underway for Next Clinical Study in U.S. SAN DIEGO, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO) today announced week 26 results from its Phase 1b/2a clin...
GlobeNewswire · 02/16 13:00
DSS, MARA and BNGO among premarket losers
Document Security Systems (DSS) -31% on stock offering.Gevo (GEVO) -25% on stock offering.BioLineRx (BLRX) -22% on equity offering.Bionano Genomics (BNGO) -19% on pricing of stock offering.Histogen (HSTO) -12% on FDA clinical hold of planned study
Seekingalpha · 01/20 13:31
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 19)
Benzinga · 01/20 12:32
Histogen announces FDA clinical hold of planned study for HST-003
Histogen (HSTO) has lost 17.8% in value in postmarket trading after the company announced that the FDA has sought additional questions regarding its Investigational New Drug (“IND”) application for the planned Phase 1/2 clinical
Seekingalpha · 01/19 22:12
DJ Histogen New Drug Application Expected to be Put on Hold by FDA; Shares Fall
Dow Jones · 01/19 21:28
Histogen falls after FDA clinical hold on HST-003 study in knee tissue regeneration
Histogen (HSTO) drops 22% after hours in reaction to FDA's clinical hold on the company's planned Phase 1/2 trial to evaluate the safety and efficacy for HST-003 for knee cartilage regeneration.The agency
Seekingalpha · 01/19 21:21
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HSTO. Analyze the recent business situations of Conatus Pharmaceuticals through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HSTO stock price target is 1.500 with a high estimate of 1.500 and a low estimate of 1.500.
EPS
Institutional Holdings
Institutions: 57
Institutional Holdings: 1.54M
% Owned: 5.31%
Shares Outstanding: 29.03M
TypeInstitutionsShares
Increased
3
4.21K
New
7
44.65K
Decreased
5
108.20K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.24%
Pharmaceuticals & Medical Research
+1.32%
Key Executives
Chairman/Director
David Crean
President/Chief Executive Officer/Director
Richard Pascoe
Founder/Chief Scientific Officer
Gail Naughton
Chief Financial Officer/Executive Vice President
Susan Knudson
Executive Vice President
Moya Daniels
Senior Vice President
Daniel Ripley
Senior Vice President
Edward Smith
Vice President - Operations
Martin Latterich
Secretary
Thomas Hubka
Director
Stephen Chang
Director
Jonathan Jackson
Director
Steven Mento
Director
Brian Satz
Director
Hayden Yizhuo Zhang
Independent Director
Daniel Kisner
  • Dividends
  • Splits
  • Insider Activity
No Data
About HSTO
Histogen Inc., formerly Conatus Pharmaceuticals Inc., is a regenerative medicine company. The Company is focused on developing technologies that replace and regenerates tissues in the body. The company’s technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells, developing therapeutic products that address unmet medical needs. The Company has product candidates in clinical development intended to address and offer treatment for hair loss, dermal filler and treatment for joint cartilage repair. The Company manufactures a soluble multipotent cell conditioned media (CCM), which is the starting material for products for hair growth, skin care and other applications. In addition to this, the Company also manufactures an insoluble extracellular matrix (ECM) for applications such as orthopedics, wound care and soft tissue augmentation.

Webull offers kinds of Histogen Inc stock information, including NASDAQ:HSTO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HSTO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HSTO stock methods without spending real money on the virtual paper trading platform.